TG Therapeutics: Business Model, SWOT Analysis, and Competitors 2026

TG Therapeutics, Inc. stands as a leading company in Healthcare. Generating $616.29 million in annual revenue (growing 78.0% year-over-year) and carrying a market capitalization of $4.61 billion, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, TG Therapeutics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines TG Therapeutics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating TG Therapeutics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define TG Therapeutics, Inc.'s position in the Biotechnology market today.

What You Will Learn

1. How TG Therapeutics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering TG Therapeutics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who TG Therapeutics, Inc.'s main competitors are and how the company compares on key financial metrics
4. TG Therapeutics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. TG Therapeutics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $616.29 million annual revenue (TTM), +78.0% YoY
• Market Cap: $4.61 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 83.7%, operating margin 26.2%, net margin 72.6%
• Free Cash Flow: $-43.98 million
• Return on Equity: 102.8% — strong
• Employees: 399 worldwide

Who Owns TG Therapeutics, Inc.?

TG Therapeutics, Inc. is publicly traded on the NCM under the ticker symbol TGTX. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of TG Therapeutics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

TG Therapeutics, Inc. has approximately 0.16 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $29.03 per share as of early 2026.

TG Therapeutics, Inc.'s Mission Statement

TG Therapeutics, Inc.'s strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — TG Therapeutics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For TG Therapeutics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, TG Therapeutics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does TG Therapeutics, Inc. Make Money?

As of 2026, TG Therapeutics, Inc. generates $616.29 million in annual revenue (growing 78.0% year-over-year), with a 83.7% gross margin and 26.2% operating margin. Market capitalization stands at $4.61 billion. Here is how the company generates its revenue:

How does TG Therapeutics make money?

TG Therapeutics, a biopharmaceutical company, primarily generates revenue through the development and commercialization of novel treatments for B-cell diseases. Here are the main avenues through which the company makes money:

1. Product Sales

The primary source of revenue for TG Therapeutics comes from the sales of its FDA-approved drugs. These medications are designed to target and treat specific types of B-cell malignancies and autoimmune diseases. As the company continues to develop and bring new drugs to market, product sales are expected to grow significantly.

2. Licensing Agreements

TG Therapeutics often enters into licensing agreements with other pharmaceutical companies. These agreements allow TG Therapeutics to out-license certain drug candidates or technologies, providing the company with upfront payments, milestone payments, and royalties on future sales. Such partnerships can be lucrative and provide a steady stream of income while sharing the risks associated with drug development.

3. Research and Development Collaborations

The company engages in research and development collaborations with academic institutions, research organizations, and other biotech firms. These collaborations can be a source of revenue through grants, funding support, and shared intellectual property. Additionally, successful collaborations can lead to the co-development of new therapies, expanding TG Therapeutics' product pipeline.

4. Government and Private Grants

TG Therapeutics may also receive grants from government agencies, non-profit organizations, and private entities that support innovative research in the field of oncology and autoimmune diseases. These grants provide essential funding for early-stage research and development projects, helping to offset some of the costs associated with bringing new therapies to market.

5. Equity Financing and Public Offerings

While not a direct source of operational revenue, TG Therapeutics raises capital through equity financing and public offerings. By issuing shares of stock, the company can secure significant funding from investors, which is then used to support ongoing research, clinical trials, and commercialization efforts. This financial strategy is crucial for sustaining long-term growth and development.

6. Strategic Partnerships and Acquisitions

From time to time, TG Therapeutics may enter into strategic partnerships or acquisitions to enha

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review TG Therapeutics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

TG Therapeutics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how TG Therapeutics, Inc. creates, delivers, and captures value.

Key Partners: TG Therapeutics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: TG Therapeutics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: TG Therapeutics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (399 employees), proprietary technology, and financial resources ($141.97M in cash).

Value Propositions: TG Therapeutics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: TG Therapeutics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: TG Therapeutics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: TG Therapeutics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: TG Therapeutics, Inc.'s major costs include cost of goods sold (16.3% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 73.8% of revenue.

Revenue Streams: TG Therapeutics, Inc. generates revenue through its core product and service offerings.

TG Therapeutics, Inc. Competitors

TG Therapeutics, Inc.'s main competitors include Roche (Genentech), AbbVie, Bristol, AstraZeneca, Novartis. The company operates in the Biotechnology segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

TG Therapeutics, Inc.'s competitive position in Biotechnology is defined by its $4.61B market capitalization and 83.7% gross margins. Key competitive advantages include brand recognition and operational scale in the Biotechnology market.

TG Therapeutics, Inc. SWOT Analysis

A SWOT analysis examines TG Therapeutics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: TG Therapeutics, Inc.'s gross margin of 83.7% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 26.2% demonstrates disciplined cost management even at scale.
• Revenue Growth: Revenue grew 78.0% year-over-year to $616.29M, indicating strong demand for TG Therapeutics, Inc.'s products and services and outperformance relative to many industry peers.
• Capital Efficiency: A return on equity of 102.8% demonstrates that TG Therapeutics, Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.

Weaknesses

• Competitive Scale Pressure: In the Biotechnology sector, larger competitors with greater economies of scale can exert pricing pressure and outspend TG Therapeutics, Inc. on marketing, R&D, and distribution — limiting the company's ability to defend market share in a price-sensitive environment.
• Market Concentration Risk: Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strategic challenge.

Opportunities

• Total Addressable Market: TG Therapeutics, Inc. operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for TG Therapeutics, Inc.'s products and services.
• Strategic Acquisitions: With $141.97M in cash and strong free cash flow generation, TG Therapeutics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. TG Therapeutics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on TG Therapeutics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

TG Therapeutics, Inc. enters 2026 as a leading company in Healthcare, backed by $616.29 million in annual revenue and a 72.6% net profit margin. The company's 83.7% gross margins and $-43.98 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in TG Therapeutics, Inc.'s core markets.

For investors, TG Therapeutics, Inc.'s 10.5x trailing P/E and 11.6x forward P/E reflect the market's expectations for continued strong growth. Analysts and investors should watch quarterly earnings releases, management commentary on comparable sales growth, margin trends, and capital allocation for signals of how the investment thesis is progressing.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – TG Therapeutics, SEC EDGAR – TG Therapeutics Filings, and TG Therapeutics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. Is TG Therapeutics a good buy?

TG Therapeutics, Inc. generated $616.29 million in annual revenue with a 72.6% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult TG Therapeutics, Inc.'s investor relations page.

2. How much debt is TG Therapeutics in?

TG Therapeutics, Inc. generated $616.29 million in annual revenue (trailing twelve months), a 78.0% increase year-over-year. The company's gross margin is 83.7%, reflecting its pricing power in the Biotechnology market.

3. Who are the competitors of TG Therapeutics?

TG Therapeutics, Inc. competes in the Biotechnology segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Biotechnology center on product differentiation, pricing strategy, and distribution scale.

4. Why did TGTx stock drop?

TG Therapeutics, Inc. generated $616.29 million in annual revenue with a 72.6% net profit margin as of the latest reporting period. The company operates in the Biotechnology sector. For the most current information, consult TG Therapeutics, Inc.'s investor relations page.

5. What does TG Therapeutics, Inc. do?

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatm

6. How much revenue does TG Therapeutics, Inc. make?

TG Therapeutics, Inc. generated $616.29 million in annual revenue (TTM), with 78.0% year-over-year growth.

7. What is TG Therapeutics, Inc.'s market cap?

TG Therapeutics, Inc.'s market capitalization is approximately $4.61 billion as of early 2026.

8. Is TG Therapeutics, Inc. profitable?

Yes. TG Therapeutics, Inc. has a net profit margin of 72.6% and a return on equity of 102.8%.

9. Who are TG Therapeutics, Inc.'s competitors?

TG Therapeutics, Inc. competes in the Biotechnology sector against companies including Roche (Genentech), AbbVie, Bristol.

10. Does TG Therapeutics, Inc. pay dividends?

TG Therapeutics, Inc. does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.